JP2013503165A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503165A5
JP2013503165A5 JP2012526812A JP2012526812A JP2013503165A5 JP 2013503165 A5 JP2013503165 A5 JP 2013503165A5 JP 2012526812 A JP2012526812 A JP 2012526812A JP 2012526812 A JP2012526812 A JP 2012526812A JP 2013503165 A5 JP2013503165 A5 JP 2013503165A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
neurotoxin
type
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012526812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503165A (ja
JP5766699B2 (ja
Filing date
Publication date
Priority claimed from US12/548,073 external-priority patent/US8147848B2/en
Application filed filed Critical
Publication of JP2013503165A publication Critical patent/JP2013503165A/ja
Publication of JP2013503165A5 publication Critical patent/JP2013503165A5/ja
Application granted granted Critical
Publication of JP5766699B2 publication Critical patent/JP5766699B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012526812A 2009-08-26 2010-08-10 ボツリヌス神経毒素により早漏を処置する方法 Expired - Fee Related JP5766699B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/548,073 2009-08-26
US12/548,073 US8147848B2 (en) 2009-08-26 2009-08-26 Method for treating premature ejaculation with a botulinum neurotoxin
PCT/US2010/044959 WO2011028371A1 (en) 2009-08-26 2010-08-10 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015122108A Division JP6078108B2 (ja) 2009-08-26 2015-06-17 ボツリヌス神経毒素により早漏を処置する方法

Publications (3)

Publication Number Publication Date
JP2013503165A JP2013503165A (ja) 2013-01-31
JP2013503165A5 true JP2013503165A5 (enExample) 2013-10-31
JP5766699B2 JP5766699B2 (ja) 2015-08-19

Family

ID=43127150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012526812A Expired - Fee Related JP5766699B2 (ja) 2009-08-26 2010-08-10 ボツリヌス神経毒素により早漏を処置する方法
JP2015122108A Expired - Fee Related JP6078108B2 (ja) 2009-08-26 2015-06-17 ボツリヌス神経毒素により早漏を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015122108A Expired - Fee Related JP6078108B2 (ja) 2009-08-26 2015-06-17 ボツリヌス神経毒素により早漏を処置する方法

Country Status (18)

Country Link
US (8) US8147848B2 (enExample)
EP (2) EP2470202B1 (enExample)
JP (2) JP5766699B2 (enExample)
KR (1) KR101612988B1 (enExample)
CN (2) CN103816530B (enExample)
AU (2) AU2010289969B2 (enExample)
BR (1) BR112012004246A2 (enExample)
CA (1) CA2772372C (enExample)
CY (1) CY1114792T1 (enExample)
DK (2) DK2470202T3 (enExample)
ES (2) ES2564677T3 (enExample)
IN (1) IN2012DN02210A (enExample)
MX (2) MX349947B (enExample)
PL (1) PL2470202T3 (enExample)
PT (1) PT2470202E (enExample)
RU (1) RU2568844C2 (enExample)
SI (1) SI2470202T1 (enExample)
WO (1) WO2011028371A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US20120251518A1 (en) * 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20130066148A1 (en) * 2011-09-12 2013-03-14 Kang Seon Cho Method of augmenting glans
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
US9764010B2 (en) * 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin
DK3188706T3 (da) * 2014-09-02 2020-01-20 American Silver Llc Botulinumtoksin og kolloide sølvpartikler
RU2565104C1 (ru) * 2014-10-24 2015-10-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения преждевременной эякуляции
AU2018270092C1 (en) * 2017-05-18 2026-01-08 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
WO2018220232A1 (en) * 2017-06-02 2018-12-06 Universite De Versailles-St Quentin En Yvelines Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction
US12102556B2 (en) 2022-05-31 2024-10-01 Max Azevedo System and method for fallopian birth control
US12337014B1 (en) 2024-06-17 2025-06-24 Enrico Guarino Intracavernosal gel infusion system with neurotoxin modulation for erectile function
WO2026118698A1 (en) * 2024-12-03 2026-06-11 Obigen Pharma, Inc. Novel use of clostridium botulinum toxin type a for treatment of glabellar lines

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
DE69434535T2 (de) 1993-12-28 2006-07-20 Allergan, Inc., Irvine Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CN1123680A (zh) * 1994-11-18 1996-06-05 吕建京 一种对于肺脾肾虚有良好功效的保健品及其制造方法
ATE320815T1 (de) 1997-07-15 2006-04-15 Univ Colorado Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
CN1146866C (zh) * 1998-11-17 2004-04-21 阿尔卑斯电气株式会社 浮起式磁头的冠顶形成方法及冠顶形成装置
FR2793689B1 (fr) 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
RU2180591C2 (ru) * 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
NZ528935A (en) 2001-03-16 2004-10-29 Dmi Biosciences Inc Method of delaying ejaculation
CZ20032644A3 (en) 2001-03-29 2004-06-16 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
DK1474143T3 (da) * 2002-01-25 2009-01-26 Modular Properties Ltd Fremgangsmåder og sammensætninger til bahandling af mandlig erektil dysfunktion
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
TW200418838A (en) * 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
WO2005072433A2 (en) * 2004-01-26 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Toxin induced sympathectomy
US20060100584A1 (en) 2004-08-10 2006-05-11 Orest Olejnik Needleless microprotrusion elastoplast system
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
CN1682810A (zh) * 2005-02-22 2005-10-19 黄资源 一种治疗前列腺疾病的前列外敷散
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
WO2007059528A2 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7445783B2 (en) 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
US20090005319A1 (en) * 2007-07-01 2009-01-01 Barone Jr Frank V Topical compositions for delaying ejaculation and methods of using the same
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation
CA2703370A1 (en) 2007-10-23 2009-04-30 Allergan, Inc. Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US9049616B2 (en) 2012-03-29 2015-06-02 Broadcom Corporation Session recovery after network coordinator or AP restart for single user, multiple user, multiple access, and/or MIMO wireless communications
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin

Similar Documents

Publication Publication Date Title
JO3813B1 (ar) أحماض دهنية جديدة واستخدامها بالاقتران مع جزيئات حيوية
JP2010222367A5 (enExample)
JP2015518818A5 (enExample)
NZ719520A (en) Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
JP2007514749A5 (enExample)
WO2012170899A3 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
JP2014505733A5 (enExample)
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
AU2016204185A1 (en) Methods of administering beta7 integrin antagonists
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
JP2015509961A5 (enExample)
IN2012DN02210A (enExample)
JP2013540803A5 (enExample)
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
BR112013010345A2 (pt) tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
BRPI0602397C1 (pt) composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv